COMMUNIQUÉS West-GlobeNewswire

Candel Therapeutics Announces Pricing of Public Offering
20/02/2026
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results
20/02/2026
Quarterly revenue of $748 million ; GAAP loss of ($0.20) /share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent [...]
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
19/02/2026
SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating [...]
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
19/02/2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
19/02/2026
Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when [...]
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
19/02/2026
RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate cancer [...]
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
19/02/2026
Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, Nasdaq: [...]
Sienna Reports Fourth Quarter 2025 Financial Results and Continues Platform Growth
19/02/2026
MARKHAM, Ontario, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and twelve months ended December 31, 2025. [...]
Magnesium Niacinamide Relief Topical Cream: What Consumers Are Researching Before Buying in 2026
20/02/2026
An informational overview of publicly available disclosures for Magnesium Niacinamide Relief (MagnesiumFreeze) — covering ingredients, company policies, and what consumers researching topical nerve discomfort and [...]
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
19/02/2026
LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern [...]
Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors
19/02/2026
Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today [...]
Curaechoice and The Center for Pain to Deliver No-Cost Pain Management to Members Nationwide
19/02/2026
Curaechoice Members and Their Families Now Have Access to Comprehensive Pain Management Services from The Center for Pain, a Clearway Company, at $0 Cost. Birmingham, ALABAMA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
19/02/2026
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for [...]
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
19/02/2026
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases [...]
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
19/02/2026
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD [...]
Candel Therapeutics Announces Proposed $100 Million Public Offering
19/02/2026
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
19/02/2026
On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with [...]
ICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance
19/02/2026
SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
19/02/2026
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally [...]

Pages